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ABSTRACT
A balanced interaction between osteoblast and osteoclast plays a major role in maintaining bone strength and structural 
integrity. Tocotrienol, a palm derivative with potent antioxidant properties showed an anti-osteoporotic effect but little 
is known about its mechanism of action. Hence, this research was conducted to determine the effects of palm tocotrienol 
on the surface osteoblast and osteoclast of the the glucocorticoid-induced osteoporotic bones. The study involved 
40 male Sprague-Dawley rats weighing 250-300 g which were randomly divided into an equal number of Baseline, 
Sham, Adrx+Dexa (adrenalectomized with dexamethasone), Adrx+Dexa+ATF (adrenalectomized with dexamethasone 
supplemented with α-tocopherol) and Adrx+Dexa+PTT (adrenalectomized with dexamethasone supplemented with 
palm tocotrienol). Bloods were taken prior to sacrifice for serum biomarkers and either tibia or femur was harvested 
for bone biomarkers, gene expressions analysis and histological studies. A double-blinded experiment was performed 
to calculate the number of total cells (osteoblasts and osteoclast) with intact nuclei within five fields of view. While 
serum osteocalcin and gene expression did not show any changes, CTX level was increased in the Adrx+Dexa group 
but reduced after the supplementation of palm tocotrienol. Supplementation of palm tocotrienol also significantly 
decrease the osteoclast population (p<0.05) compared to Adrx+Dexa group. In contrast, osteoblast population showed 
no significant difference across the groups. The result showed that palm tocotrienol acts by modulating the osteoclasts 
but not osteoblast, which revert the dynamics of bone cells population in the osteoporotic bone to its pre-osteoporotic 
levels. Supplements of tocotrienol in daily diet may be beneficial in preventing osteoporosis.
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ABSTRAK
Interaksi seimbang antara osteoblas dan osteoklas memainkan peranan utama dalam mengekalkan kekuatan dan 
integriti struktur tulang. Tokotrienol, terbitan sawit dengan sifat antioksidan yang kuat telah menunjukkan kesan 
anti-osteoporosis tetapi amat sedikit diketahui tentang mekanisme tindakannya. Oleh yang demikian, kajian ini 
dijalankan untuk menentukan kesan tokotrienol sawit ke atas sel permukaan osteoblas dan osteoklas pada tulang 
osteoporosis aruhan glukokortikoid. Kajian ini melibatkan 40 ekor tikus Sprague-Dawley jantan dengan berat antara 
250-300 g yang dibahagikan secara rawak kepada kumpulan Kawalan, Sham, Adrx+Dexa (adrenalektomi dengan 
deksamethason), Adrx+Dexa+ATF (adrenalektomi dengan deksamethason ditambah α-tokoferol) dan Adrx+Dexa+PTT 
(adrenalektomi dengan deksamethason ditambah tocotrienol sawit) secara oral selama dua bulan. Darah diambil 
daripada tikus sebelum dikorbankan dan tulang tibia atau femur kemudiannya diambil untuk kajian petanda biokimia 
dan histologi. Kajian ‘double blinded’ dilakukan dengan  menghitung jumlah keseluruhan sel (osteoblas dan osteoklas) 
dengan nukleus dalam lima medan pandangan. Sementara serum osteokalsin dan ekspresi gen tidak menunjukkan 
sebarang perubahan, aras CTX meningkat pada kumpulan Adrx+Dexa tetapi menurun dengan suplementasi tocotrienol 
sawit. Suplementasi tocotrienol sawit juga menyebabkan penurunan ketara bilangan osteoklas (p<0.05) berbanding 
kumpulan Adrx+Dexa. Sebaliknya, populasi osteoblas tidak menunjukkan perbezaan yang signifikan pada kesemua 
kumpulan. Keputusan kajian menunjukkan bahawa tokotrienol sawit bertindak dengan memodulasi osteoklas tetapi 
bukan osteoblas yang mengembalikan dinamik osteoblas dan populasi osteoblas dalam tulang osteoporosis  ke tahap 
pra-osteoporosis. Tambahan tokotrienol  dalam diet harian mampu memberi manfaat dalam mencegah osteoporosis.
Kata kunci: Antioksidan; osteoblas; osteoklas; osteoporosis; vitamin E
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INTRODUCTION
Osteoblasts are mesenchymal derived from mesodermal 
and neural crest progenitors that involved in bone 
formation (Khosla et al. 2008). Most of the bone 
matrix proteins such as type I collagen, proteoglycans 
and osteocalcin are secreted and deposited by mature 
osteoblasts. Osteoblasts are also responsible in regulating 
the formation of hydroxyapatite crystals in osteoid. 
Conversely, the differentiation of monocyte-macrophage 
precursor cells at the bone matrix created a tissue-specific 
macrophage polykaryon called osteoclast. Osteoclast 
undergoes internal structural changes that prepare it to 
resorb bone by rearrangements of the actin cytoskeleton 
and formation of a tight junction between the bone surface 
and basal membrane to form a sealed compartment (Boyle 
et al. 2003). These changes occur in response to activation 
of receptor activator of nuclear factor kappa-Β ligand 
(RANKL) (Clarke 2008). 
 The interaction between osteoblasts and osteoclasts 
is known as coupling and it is essential for maintaining 
a balance between the rates of bone formation and 
resorption (Lemaire et al. 2004). Imbalanced activity 
between osteoclasts and osteoblasts can arise from various 
factors such as hormonal changes, enhanced production 
of inflammatory cytokines or growth factors. These can 
result in either decreased or increased bone mass. While 
the increased in bone mass can be seen in osteopetrosis, 
a heterogeneous group of rare heritable conditions, bone 
loss is far more prevalent and observed in many diseases 
such as in chronic infections, periodontitis, rheumatoid 
arthritis, leukemia, postmenopausal osteoporosis and lytic 
bone metastases (Leibbrandt & Penninger 2008). 
 Osteoporosis is a skeletal condition characterized 
by decreased density of normally mineralized bone 
that impairs the mechanical strength of the bone and 
making it vulnerable to fracture (Glaser & Kaplan 1997). 
There are two types of osteoporosis which are primary 
and secondary osteoporosis. Primary osteoporosis is 
mainly a skeletal disorder of postmenopausal women 
(postmenopausal osteoporosis) or of older men and women 
(senile osteoporosis). Meanwhile, secondary osteoporosis 
refers to bone loss resulting from specific clinical disorders 
such as thyrotoxicosis or hyperadrenocorticism (Marcus 
1996). Bone loss and eventually fractures are the hallmarks 
of osteoporosis, regardless of the underlying cause or 
causes. The excessive activity of osteoclast and inadequate 
activity of osteoblast are the responsible pathology of the 
imbalance between the formation and resorption of bone 
in postmenopausal and age related osteopenia (Manolagas 
2000).
 Recent studies have shown that free radicals and lipid 
peroxidation play an important role in bone metabolism 
especially in osteoblast and osteoclast activity. These 
free radicals are found to be cytotoxic to osteoblast. As 
a potent antioxidant, vitamin E was able to maintain 
bone matrix trophism and stimulate trabecular bone 
formation. It was supported by other studies which 
showed that bone impairment caused by an oxidizing 
agent, ferric nitrilotriacetate, can be prevented by vitamin 
E supplementation (Maniam et al. 2008). Vitamin E exists 
in the form of tocopherols and tocotrienols. Both have 
several type of isomers known as alpha, beta, gamma 
and delta (Traber 2007). Structurally, tocopherols consist 
of a chromanol ring and a 15-carbon tail derived from 
homogentisate (HGA) and phytyl diphosphate. Tocotrienols 
differs from tocopherols by the presence of three trans 
double bonds in the hydrocarbon tail. The primary form of 
tocotrienols in vitamin E is found in the seed endosperm 
of most monocots, such as wheat, rice and barley (Sen et 
al. 2006). Tocotrienol are found more abundant in palm, 
rice and annatto fruit (Tan et al. 2012).
 Based on various studies, tocotrienol have shown 
to exhibit antioxidant, antiproliferative, antiangiogenic 
and anti-inflammatory activities (Aggarwal et al. 2010). 
In addition, tocotrienol also exhibit neuroprotective and 
cholesterol lowering activity by inhibiting the activity of 
HMG-CoA reductase (Das et al. 2008). It also possesses 
anti-cancer and anti-diabetic properties (Aggarwal et al. 
2010). 
 The aim of this research was to determine the 
effects of palm tocotrienol on the glucocorticoid-induced 
osteoporotic bones. In this study, the number of osteoblasts 
and osteoclasts in osteoporotic bones were observed when 
the tocotrienols isomer of vitamin E, mainly derived from 
palm were used. Decalcified bone samples from either 
tibia or femur were used for the analysis of the histological 
parameters. Using specific biochemical markers, the 
activities of osteoblasts and osteoclasts in both variables 
were analyzed.
MATERIALS AND METHODS
ANIMAL AND TREATMENT
All procedures were carried out in accordance with the 
institutional guidelines for animal research surgical 
procedures of the Universiti Kebangsaan Malaysia (UKM) 
Research and Animal Ethics Committee (UKMAEC).
 Forty three-month-old male Sprague-Dawley rats 
weighing about 250-300 g were obtained from the Universiti 
Kebangsaan Malaysia (UKM) Animal Breeding Centre. The 
animals were randomly divided into five groups (n=8) 
comprising of baseline (Baseline), sham operated (Sham) 
and three experimental groups supplemented with either 
palm olein (Adrx+Dexa), α-tocopherol (Adrx+Dexa+ATF) 
or palm tocotrienol (Adrx+Dexa+PTT). Adrenalectomy 
was performed on the Adrx+Dexa, Adrx+Dexa+ATF and 
Adrx+Dexa+PTT groups two days after receiving the 
animals. The rats were anaesthetized before the dorsal 
midline and bilateral flank muscle incisions were made. 
The adrenal glands were identified and the vessels were 
ligated to avoid bleeding before the removal of the glands. 
The incisions were sutured and the wounds were cleaned. 
Poviderm© cream was applied to the wound daily for five 
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days to prevent infection and also to aid in wound healing. 
The sham operated rats underwent the similar procedure 
except that the adrenal gland was left in-situ. 
 Two weeks post-adrenalectomy procedure, the 
rats were given 120 μg/kg dose of dexamethasone 
through intramuscular injection and followed with 
the administration of the following supplements; 
Adrx+Dexa+ATF received 60 mg/kg/day of α-tocopherol 
and Adrx+Dexa+PTT received 60 mg/kg/day of palm 
tocotrienol. The positive control group, Adrx+Dexa group 
was also given intramuscular dexamethasone and received 
orally 0.05 mL/100 g/day of palm olein. Palm olein is the 
vehicle used to deliver α-tocopherol and palm tocotrienol. 
All supplements were delivered via gastric gavage for six 
days a week for two months. The palm tocotrienol used in 
this study was provided by Sime Darby Bhd.
 The animals were placed in clean cages under 12 h 
light and dark cycles. They were fed with rat pellets (Gold 
Coin, Malaysia) ad libitium. The adrenalectomized rats 
were provided with normal saline to drink ad libitium to 
replace the salt loss due to mineralocorticoid deficiency 
post-adrenalectomy, while the Sham group was given tap 
water. After two months of supplementations, the animals 
were euthanized and their tibia or femur was extracted. 
SAMPLE COLLECTION
Blood were taken before the commencement and after the 
completion of the treatment. They were centrifuged at 3000 
rpm at 4°C for 15 min and the serum was kept in aliquots 
at -80°C until analyzed.
 Both tibia and femur bones from each rats were 
cleaned and fixed using periodate-lysine-paraformaldehyde 
for 24 h at 4°C. This is followed with washing using three 
solutions, 0.01M PBS containing 5% glycerol, 0.01M 
PBS containing 10% glycerol and 0.01M PBS containing 
15% glycerol for 12 h at 4°C to decalcify the tissue. The 
specimens were further decalcified using EDTA-G solution 
for 10 to 14 days at 4°C. This solution was replaced every 5 
days and the progression of decalcification was monitored 
every 24 h by micro X-ray.
 Once decalcified, the reagent was washed several 
times using specific concentration of solutions, of 15% 
sucrose and 15% glycerol in PBS, 20% sucrose and 10% 
glycerol in PBS, 20% sucrose and 5% glycerol in PBS, 
20% sucrose in PBS, 10% sucrose in PBS, 5% sucrose in 
PBS and lastly100% PBS. The decalcified tissues was then 
dehydrated in a series of alcohol and embedded in paraffin 
using an automatic tissue processor.
SERUM BONE BIOMARKERS ANALYSIS
Serum bone biomarkers were analyzed by utilizing the 
ELISA method. For serum resorption markers, carboxy-
terminal collagen cross links (CTX) were measured using 
the Cross Linked C-Telopeptide of Type 1 Collagen 
Kit (Uscn Lifescience Inc. Wuhan, China), whereas 
serum osteocalcin was analyzed using the ELISA kit 
(Immunodiagnostic Systems Limited, UK). The serum used 
was obtained prior to the rats being sacrificed.
RANKL/OPG RATIO GENE EXPRESSION MEASUREMENTS
A fraction of the trabecular bone tissue (~5 mg) was 
obtained from the distal part of left femurs and placed 
into a vial containing magnetic beads. One vial was used 
for each sample. A mixture of 300 μL of Homogenising 
Solution (provided in the QG Sample Preparation Kit for 
Tissue) and 3 μL of Proteinase K (provided in the QG 
Sample Preparation Kit for Tissue) were added into the vial. 
The vials were later placed into Cell Rupture equipment 
for 15-30 s for 2 cycles followed by a quick spin for 5 
s. The vials were then incubated in a warm water bath 
at 65ºC for 60 min and spun at 13,000 rpm for 10 min 
at room temperature. The homogenate/supernatant was 
transferred into a microcentrifuge tube and stored at -80ºC 
until used. The kits used for this procedure were supplied 
by Affymatrix Thermo Fisher Scientific, USA.
TISSUE SECTIONING
The paraffin block of each group was trimmed using 
microtome to produce five samples with the thickness of 5 
micrometers each. These samples were floated on a water 
bath at 48°C and collected under Poly-L-lysine coated 
glass slides. The slides were stained histochemically with 
Alkaline Phosphatase (ALP) and Hematoxylin and Eosin 
(H&E) to observe osteoblast and osteoclast population, 
respectively.
HISTOLOGICAL DEMONSTRATION OF ALP FOR OSTEOBLAST
ALP histochemistry was performed following a modified 
version of a previously described method by Miao et 
al. (2002). The tissue section was deparaffinised and 
hydrated with xylene, followed by a series of alcohol 
graded solution. The slides were soaked overnight in 
1% magnesium chloride in 100 mm Trismaleate buffer 
(pH9.2). prior to incubation with ALP substrate solution 
(freshly prepared) which contain 100 mM Tris-maleate 
buffer (pH9.2), 0.2 mg/mL naphthol AS-MX phosphate 
and 0.5 mg/mL Fast Red TR for 2 h in room temperature. 
After washing the section tissue with distilled water, Vector 
methyl green nuclear were used to counterstain the sample 
for 20 s and mounted with Kaiser’s glycerol jelly.
HISTOLOGICAL DEMONSTRATION USING                                     
H&E STAINING FOR OSTEOCLAST
Hematoxylin and Eosin (H&E) histology was performed 
using the standard protocol. The slides were deparaffinized 
and rehydrated by using graded alcohol to distilled water. 
After hydration process, the slides were stained in Tacha’s 
CAT Hematoxylin for 1 min. The slides were then washed 
4-5 times with tap water and fixed with Phosphate Buffer 
Saline (PBS) pH7.2 to 7.3 for 1 min. The slides were rinsed 
with three changes of distilled water before counterstained 
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in Alcoholic-Eosin for 1 min. The Alcoholic-Eosin reagent 
contains 50.0 mL 1.0% Eosin Y (mixture of 1.0 g Eosin 
Y and 100 mL distilled water), 5.0 mL 1.0% Phloxine B 
(0.5 g Phloxine B in 50.0 mL distilled water), 390.0 mL 
95% Ethanol and 4.0 mL Acetic Acid, glacial. The slides 
were then dehydrated through a series of three changes 
of 95% Ethyl Alcohol (EtOH) and two changes of 100% 
EtOH for 1 min each. This is followed by three changes of 
Xylene for 1 min each to clear the slides before covering 
with coverslips. 
DATA COLLECTION FOR HISTOLOGICAL SECTION
The total number of cells (osteoblasts and osteoclast) with 
intact nuclei were observed at ×200 magnification at five 
different areas per section. A double-blinded experiment 
was performed to calculate the total number of cells using 
Weibel point counting method prior to statistical analysis. 
STATISTICAL ANALYSIS
The population of osteoblast and osteoclast from  different 
treatment groups were compared using one-way analysis 
of variance (ANOVA) followed by the Tukey post hoc test. 
Data analysis was done using Statistical Package for Social 
Sciences (SPSS) version 23 (IBM, Armonk, USA). Values 
were considered statistically significant at p<0.05. All data 
were presented as mean ± standard error of mean.
RESULTS AND DISCUSSION
SERUM BIOMARKER ANALYSIS
Continuous treatment of dexamethasone for two-months 
did not produce any significant changes to the serum 
osteocalcin level between Adrx+Dexa against Baseline and 
Sham groups. Supplementation of α-tocopherol or PTT also 
bears no effect on the level of osteocalcin (Figure 1(a)). 
In contrast, serum CTX level showed a significant increase 
in the Adrx+Dexa group compared to the Baseline and 
Sham group (p<0.05). Supplementation with α-tocopherol 
(Adrx+Dexa+ATF) and palm tocotrienol (Adrx+Dexa+PTT) 
significantly lowered the CTX level (p<0.05) compared to 
Adrx+Dex group. CTX level between Adrx+Dexa+TT and 
Sham groups were not significantly different (Figure 1(b)).
GENE EXPRESSION ANALYSIS
Osteocalcin gene expression, which is often used as a 
marker for bone formation process were found to be 
significantly lowered in Sham, Adrx+Dexa+ATF and 
Adrx+Dexa+PTT groups compared to Baseline and 
Adrx+Dexa groups (Figure 2(a)). However, two months 
treatment caused decrease in bone resorption related gene 
expression of RANKL/OPG Ratio in Sham group compared to 
Adrx+Dexa and Adrx+Dexa+ATF groups. Supplementation 
with palm tocotrienol caused no significant changes to the 
RANKL/OPG ratio (Figure 2(b)).
FIGURE 1(a). Serum osteocalcin. Data presented as mean + SEM. 
Baseline = baseline control; Sham = sham operated control; 
Adrx+Dexa = adrenalectomized and given intramuscular 
dexamethasone 120 μg /kg/day;  Adrx+Dexa+ATF = 
adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and α-tocopherol 60 mg/kg/day; Adrx+Dexa+PTT = 
adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and oral palm tocotrienol 60 mg/kg/day)
FIGURE 1(b). Serum Cross Linked C-Telopeptide of Type 
1 Collagen (CTX). Data presented as mean + SEM. Same 
alphabets indicate significant difference between treatment 
groups at p<0.05. Baseline = baseline control; Sham = sham 
operated control; Adrx+Dexa = adrenalectomized and given 
intramuscular dexamethasone 120 μg/kg/day; Adrx+Dexa+ATF 
= adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and α-tocopherol 60 mg/kg/day; Adrx+Dexa+PTT = 
adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and oral palm tocotrienol 60 mg/kg/day)
EFFECTS OF THE SUPPLEMENTS TO THE PERCENTAGE OF 
SURFACE OSTEOBLAST
The percentage of osteoblast on the surface of normal 
bone and experimental rats using ALP staining are shown 
in Figure 3. Following the surgery and supplementation, 
no significant differences across the groups (p>0.05) were 
recorded. The surface osteoblasts are shown (arrowhead) 
in Photomicrograph 1 and are spread evenly across groups. 
These cells lie on the bone surface with spindle-shaped 
formation, indicating its inactive stage.
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EFFECTS OF THE SUPPLEMENTS TO THE PERCENTAGE OF 
SURFACE OSTEOCLAST
The percentage of surface osteoclast on the bone of 
normal and supplemented rats using the conventional 
H&E is shown in Figure 4. There was a significant 
difference in percentage of surface osteoclast between 
the Sham and Adrx+Dexa group. The percentage 
of osteoclasts was also reduced significantly in the 
Adrx+Dexa+PTT group when compared to Adrx+Dexa 
group (p<0.05) and Sham group (p<0.005). However, 
α-tocopherol supplemented group and the baseline group 
showed no significant differences compared to the other 
groups. The surface osteoclasts are shown (arrows) in 
Photomicrograph 2. These multinucleated cells were seen 
residing in the trabecula. 
 The effects of glucocorticoid in inducing osteoporosis 
has been long established. Glucocorticoid has been 
found to increase the oxidative stress in bone (Almeida 
et al. 2011). Removal of the adrenal gland and usage 
of glucocorticoid causing osteopenia in rats have been 
used as a model for secondary bone loss. The dosage 
of glucocorticoids used in our study was optimized by 
previous study which causes decrease in bone density 
FIGURE 2(a). Bone formation gene expression. Data presented 
as mean + SEM. Same alphabets indicate significant difference 
between treatment groups at p<0.05. Baseline = baseline control; 
Sham = sham operated control; Adrx+Dexa = adrenalectomized 
and given intramuscular dexamethasone 120 μg/kg/day; 
Adrx+Dexa+ATF = adrenalectomized and given intramuscular 
dexamethasone 120 μg/kg/day and α-tocopherol 60 mg/kg/day; 
Adrx+Dexa+PTT = adrenalectomized and given intramuscular 
dexamethasone 120 μg/kg/day and oral palm 
tocotrienol 60 mg/kg/day)
FIGURE 2(b). Bone resorption gene expression. Data presented 
as mean + SEM. Same alphabets indicate significant difference 
between treatment groups at p<0.05. Baseline = baseline control; 
Sham = sham operated control; Adrx+Dexa = adrenalectomized 
and given intramuscular dexamethasone 120 μg/kg/day; 
Adrx+Dexa+ATF = adrenalectomized and given intramuscular 
dexamethasone 120 μg/kg/day and α-tocopherol 60 mg/kg/day; 
Adrx+Dexa+PTT = adrenalectomized and given intramuscular 
dexamethasone 120 μg/kg/day and oral palm 
tocotrienol 60 mg/kg/day)
FIGURE 3. Effect of palm tocotrienol and α-tocopherol on 
surface osteoblast. Adrx+Dexa+PTT and Adrx+Dexa+ATF 
treated rats showed no differences against Adrx+Dexa, 
Sham or Baseline. Baseline = baseline control; Sham = sham 
operated control; Adrx+Dexa = adrenalectomized and given 
intramuscular dexamethasone 120 μg/kg/day; Adrx+Dexa+ATF 
= adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and α-tocopherol 60 mg/kg/day; Adrx+Dexa+PTT = 
adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and oral palm tocotrienol 60 mg/kg/day)
FIGURE 4. Effect of palm tocotrienol on the surface osteoclast. 
Adrx+Dexa+PTT was significantly reduced against Sham (b = 
p<0.005) and Adrx+Dexa (c = p<0.05), one-way ANOVA followed 
by post-hoc Tukey test. Baseline = baseline control; Sham = sham 
operated control; Adrx+Dexa = adrenalectomized and given 
intramuscular dexamethasone 120 μg/kg/day; Adrx+Dexa+ATF 
= adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and α-tocopherol 60 mg/kg/day; Adrx+Dexa+PTT = 
adrenalectomized and given intramuscular dexamethasone 120 
μg/kg/day and oral palm tocotrienol 60 mg/kg/day)
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and biomechanical strength (Elvy Suhana et al. 2012). 
Glucocorticoids causes loss of cancellous bone with 
associated histomorphometric and biochemical decrease 
in bone formation, increase bone resorption and impaired 
bone strength. Glucocorticoids act on the stem cells 
differentiation which decrease the production of osteoblast 
(De Nijs 2008). Osteoblasts secrete RANKL, an osteoclast 
activator and also osteoprotegrin, a RANKL inhibitor. 
Glucocorticoids also induces the production of RANKL 
with subsequent increase in osteoclastic activity (Mitra 
2011).
 Two months treatment with glucocorticoids was not 
sufficient to increase serum osteocalcin levels as shown 
in our results. Osteoporosis would generally decrease 
calcium and phosphorus level leading to decreased 
hydroxyapatite crystal formation. Osteocalcin is a 
calcium dependent biomarker that has a strong affinity 
with bone matrix responsible for mineralization of 
bone. Its level is expected to increase in osteoporosis 
(Jagtap et al. 2011). Bone resorption marker of CTX was 
elevated in the Adrx+Dexa group and was reduced by 
the supplementation of palm tocotrienol. This effect was 
seen in a study using tocotrienol derived from annato 
fruit (Abdul-Majeed et al. 2012) but not observed in palm 
tocotrienol before (Soelaiman et al. 2012). 
 Our study also indicates that glucocorticoid-induced 
osteoporosis is characterized by an increase in osteoclast 
population but not osteoblast population. The changes of 
osteoclast population leads to an imbalanced resorption 
activity resulting in increased porosity of the bone. The 
percentage of osteoclast surface was significantly reduced 
(p<0.05) in the tocotrienol-treated group compared to 
controlled group and the controlled group compared to 
Sham group. This result showed the effects of tocotrienol 
in producing anti-oxidant effects of reducing the 
bone resorption by reducing the percentage of surface 
osteoclasts but not osteoblast. This is in agreement with the 
previous study that indicates vitamin E effect by regulating 
the osteoclasts fusion (Fujita et al. 2012). 
 In previous study, tocotrienol have shown to exhibit 
anti-oxidant, anti-proliferative, anti-angiogenic and anti-
inflammatory activities (Aggarwal et al. 2010) which 
resulted in a prevention of bone loss and maintained bone 
microarchitecture. Tocotrienol supplementation prevent 
bone loss by increasing osteoblast survival through 
scavenging free radicals and protecting intercellular 
antioxidant defense system. Tocotrienol supplementation 
known to increase osteoblast proliferation while decreasing 
osteoclast proliferation by reducing the expression of 
pro-inflammatory cytokines that prevents IL-1 induced 
osteoclast formation (Nazrun et al. 2012). Besides 
that, it also down-regulates mevalonate pathway which 
increases osteoblast and decreases osteoclast proliferation. 
Tocotrienol supplementation also enhances expression of 
bone formation gene which conserves the bone density. Ha 
et al. (2011) found that tocotrienol specifically the alpha 
isomer, which can be found abundantly in palm tocotrienol 
has anti-bone resorptive properties by disrupting some 
of the key steps needed for osteoclastic bone resorption. 
This study also concluded that α-tocotrienol has the 
ability to inhibit the osteoclastic bone resorption by 
inhibiting nuclear factor–κB ligand (RANKL) expression 
in osteoblasts, suppressing RANKL action on osteoclast 
precursors, and reducing bone-resorbing activity of mature 
osteoclasts (Ha et al. 2011). The total cell number of 
osteoclast is not affected when its formation is inhibited 
by the α- and γ-tocotrienol isomers. However, inhibition 
of osteoclast is only exhibited by γ-tocotrienol and it was 
the most potent inhibitor of both osteoclast formation and 
activity (Brooks et al. 2011) .
CONCLUSION
This study demonstrated that the supplementation of palm 
tocotrienol has a beneficial effect in preventing osteoporosis 
by inhibiting osteoclastic activity as demonstrated by 
reducing its activity as shown by the reduced turnover 
marker CTX and histologically by reducing the number 
of osteoclast. This showed that palm-tocotrienol exert its 
anti-osteoporotic potential by inhibiting the osteoclastic 
activity but not through osteoblast augmentation. Further 
analysis is needed to support the use of palm tocotrienol 
as a supplementary diet especially in patients receiving 
long term glucocorticoid treatment.
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PHOTOMICROGRAPH 1. Bone histological section stained with ALP at 200× magnification. Surface osteoblasts 
(arrows) lie on the bone surface and mostly were in spindle-shaped form. Baseline = baseline control; Sham 
= sham operated control; Adrx+Dexa = adrenalectomized and given intramuscular dexamethasone 120 μg/
kg/day; Adrx+Dexa+ATF = adrenalectomized and given intramuscular dexamethasone 120 μg/kg/day and 
α-tocopherol 60 mg/kg/day; Adrx+Dexa+PTT = adrenalectomized and given intramuscular dexamethasone 
120 μg/kg/day and oral palm tocotrienol 60 mg/kg/day)
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PHOTOMICROGRAPH 2. Haematoxylin & eosin stain of decalcified bone at 200× magnification. Surface osteoclasts 
(arrows) observed on the bone surface and mostly residing in the trabeculae. Baseline = baseline control; Sham = 
sham operated control; Adrx+Dexa = adrenalectomized and given intramuscular dexamethasone 120 μg/kg/day; 
Adrx+Dexa+ATF = adrenalectomized and given intramuscular dexamethasone 120 μg/kg/day and α-tocopherol 
60 mg/kg/day; Adrx+Dexa+PTT = adrenalectomized and given intramuscular dexamethasone 120 μg/kg/day and 
oral palm tocotrienol 60 mg/kg/day)
